Cytokinetics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

CYTK 11.15 -0.05 (-0.45%)
price chart
Cytokinetics Inc. (CYTK) Given Buy Rating at JMP Securities
Cytokinetics Inc. logo JMP Securities restated their buy rating on shares of Cytokinetics Inc. (NASDAQ:CYTK) in a research note issued to investors on Thursday morning.
Trade: Today, Cytokinetics Inc. (CYTK) Rating Decreased to Hold at The Zacks ...  DailyQuint
FBR & Co Reaffirms "Buy" Rating for Cytokinetics Inc. (CYTK)  BBNS
Why Cytokinetics, Inc. Got Hammered Today
What happened. Cytokinetics (NASDAQ:CYTK) is down 13% heading into the closing bell Thursday after announcing plans to start a phase 3 clinical trial for its heart medication omecamtiv mecarbil.
Here's Why You Should Buy Cytokinetics, Inc. (CYTK) As Amgen, Inc. (AMGN ...  TCC
Cytokinetics (CYTK), Amgen (AMGN) to Advance Omecamtiv Mecarbil to Phase 3  StreetInsider.com
Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total revenues for the third quarter of 2016 were $59.0 million, compared to $7.9 million, during the same period in 2015.
Cytokinetics' (CYTK) CEO Robert Blum on Q3 2016 Results - Earnings Call ...  Seeking Alpha
/quotes/zigman/3870025/realtime
Cytokinetics Inc. NASDAQ: CYTK. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
Brokerages Set Cytokinetics Inc. (CYTK) Target Price at $18.33
Cytokinetics logo Shares of Cytokinetics Inc. (NASDAQ:CYTK) have been given a consensus rating of “Buy” by the nine brokerages that are covering the stock.
Today, Cytokinetics Inc. (CYTK) Given Average Recommendation of “Buy” by ...  DailyQuint
Analysts Set Cytokinetics Inc. (CYTK) Target Price at $18.33
Cytokinetics logo Shares of Cytokinetics Inc. (NASDAQ:CYTK) have earned an average recommendation of “Buy” from the nine ratings firms that are currently covering the stock.
Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total revenues for the second quarter of 2016 were $5.8 million, compared to $6.5 million, during the same period in 2015.
Cowen Positive on Cytokinetics, Inc. (CYTK) as Amgen, Inc. (AMGN) Opts-in to ...
Cowen top analyst Ritu Baral chimes in on Cytokinetics, Inc. (NASDAQ:CYTK) after Amgen, Inc. (NASDAQ:AMGN) recently opted-in to advance their collaborative drug omecamtiv mercarbil, designed to treat people living with heart failure.
JMP Securities Bullish on Cytokinetics, Inc. (CYTK) Following 2Q Update; Sees ...
In light of Cytokinetics, Inc.'s (NASDAQ:CYTK) second-quarter update, JMP Securities analyst Jason Butler remains bullish for the biotech company's pipeline drug-paved road ahead.
Cowen Reiterates Outperform on Cytokinetics, Inc. (CYTK) Following 3Q:16 Update
In a research report released Friday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Cytokinetics, Inc. (NASDAQ:CYTK) with a price target of $16, following the company's third-quarter financial results and update on its pipeline.
Price Don't Lie: Can Cytokinetics, Inc.'s Tomorrow Be Different? The ...  Frisco Fastball
Cytokinetics Inc. (CYTK) Given a $22.00 Price Target at Roth Capital  Community Financial News